Base de dados : MEDLINE
Pesquisa : C17.800.321.125 [Categoria DeCS]
Referências encontradas : 4709 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 471 ir para página                         

  1 / 4709 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29352285
[Au] Autor:Han SS; Park GH; Lim W; Kim MS; Na JI; Park I; Chang SE
[Ad] Endereço:I Dermatology, Seoul, Korea.
[Ti] Título:Deep neural networks show an equivalent and often superior performance to dermatologists in onychomycosis diagnosis: Automatic construction of onychomycosis datasets by region-based convolutional deep neural network.
[So] Source:PLoS One;13(1):e0191493, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Although there have been reports of the successful diagnosis of skin disorders using deep learning, unrealistically large clinical image datasets are required for artificial intelligence (AI) training. We created datasets of standardized nail images using a region-based convolutional neural network (R-CNN) trained to distinguish the nail from the background. We used R-CNN to generate training datasets of 49,567 images, which we then used to fine-tune the ResNet-152 and VGG-19 models. The validation datasets comprised 100 and 194 images from Inje University (B1 and B2 datasets, respectively), 125 images from Hallym University (C dataset), and 939 images from Seoul National University (D dataset). The AI (ensemble model; ResNet-152 + VGG-19 + feedforward neural networks) results showed test sensitivity/specificity/ area under the curve values of (96.0 / 94.7 / 0.98), (82.7 / 96.7 / 0.95), (92.3 / 79.3 / 0.93), (87.7 / 69.3 / 0.82) for the B1, B2, C, and D datasets. With a combination of the B1 and C datasets, the AI Youden index was significantly (p = 0.01) higher than that of 42 dermatologists doing the same assessment manually. For B1+C and B2+ D dataset combinations, almost none of the dermatologists performed as well as the AI. By training with a dataset comprising 49,567 images, we achieved a diagnostic accuracy for onychomycosis using deep learning that was superior to that of most of the dermatologists who participated in this study.
[Mh] Termos MeSH primário: Diagnóstico por Computador
Redes Neurais (Computação)
Onicomicose/diagnóstico
[Mh] Termos MeSH secundário: Adulto
Idoso
Algoritmos
Área Sob a Curva
Inteligência Artificial
Bases de Dados Factuais
Dermatologistas
Feminino
Dermatoses do Pé/diagnóstico
Dermatoses do Pé/patologia
Dermatoses da Mão/diagnóstico
Dermatoses da Mão/patologia
Seres Humanos
Interpretação de Imagem Assistida por Computador
Aprendizado de Máquina
Masculino
Meia-Idade
Onicomicose/patologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180226
[Lr] Data última revisão:
180226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180121
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0191493


  2 / 4709 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29362778
[Au] Autor:Kreijkamp-Kaspers S; Hawke KL; van Driel ML
[Ad] Endereço:Primary Care Clinical Unit, Faculty of Medicine, University of Queensland, Brisbane, Australia.
[Ti] Título:Oral Medications to Treat Toenail Fungal Infection.
[So] Source:JAMA;319(4):397-398, 2018 Jan 23.
[Is] ISSN:1538-3598
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Clinical Question: Which oral antifungal medication is associated with the highest clinical (ie, normal appearance of the toenail) and mycological (negative culture, microscopy, or both) cure rates vs placebo or other antifungals when used to treat fungal infections? Bottom Line: Both terbinafine and azole-based medications were associated with higher clinical and mycological cure rates compared with placebo (high-quality evidence). Azoles were associated with lower cure rates than terbinafine when compared directly.
[Mh] Termos MeSH primário: Antifúngicos/administração & dosagem
Azóis/administração & dosagem
Dermatoses do Pé/tratamento farmacológico
Naftalenos/administração & dosagem
Onicomicose/tratamento farmacológico
[Mh] Termos MeSH secundário: Administração Oral
Azóis/efeitos adversos
Seres Humanos
Naftalenos/efeitos adversos
Literatura de Revisão como Assunto
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antifungal Agents); 0 (Azoles); 0 (Naphthalenes); G7RIW8S0XP (terbinafine)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180131
[Lr] Data última revisão:
180131
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180125
[St] Status:MEDLINE
[do] DOI:10.1001/jama.2017.20160


  3 / 4709 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29091566
[Au] Autor:Gómez-Moyano E; Crespo-Erchiga V
[Ad] Endereço:Hospital Regional Universitario de Málaga, Malaga, Spain elisabeth.gomez.moyano@gmail.com.
[Ti] Título:HIV Infection Manifesting as Proximal White Onychomycosis.
[So] Source:N Engl J Med;377(18):e26, 2017 Nov 02.
[Is] ISSN:1533-4406
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Infecções Oportunistas Relacionadas com a AIDS/microbiologia
Dermatoses do Pé/etiologia
Infecções por HIV/complicações
Onicomicose/etiologia
Trichophyton/isolamento & purificação
[Mh] Termos MeSH secundário: Infecções por HIV/diagnóstico
Seres Humanos
Masculino
Meia-Idade
Unhas/microbiologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171109
[Lr] Data última revisão:
171109
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171102
[St] Status:MEDLINE
[do] DOI:10.1056/NEJMicm1703082


  4 / 4709 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:28707751
[Au] Autor:Kreijkamp-Kaspers S; Hawke K; Guo L; Kerin G; Bell-Syer SE; Magin P; Bell-Syer SV; van Driel ML
[Ad] Endereço:Primary Care Clinical Unit, Faculty of Medicine, The University of Queensland, Level 8, Health Sciences Building 16/910, Royal Brisbane & Women's Hospital Complex, Brisbane, Herston, Queensland, Australia, 4029.
[Ti] Título:Oral antifungal medication for toenail onychomycosis.
[So] Source:Cochrane Database Syst Rev;7:CD010031, 2017 07 14.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Fungal infection of the toenails, also called onychomycosis, is a common problem that causes damage to the nail's structure and physical appearance. For those severely affected, it can interfere with normal daily activities. Treatment is taken orally or applied topically; however, traditionally topical treatments have low success rates due to the nail's physical properties. Oral treatments also appear to have shorter treatment times and better cure rates. Our review will assist those needing to make an evidence-based choice for treatment. OBJECTIVES: To assess the effects of oral antifungal treatments for toenail onychomycosis. SEARCH METHODS: We searched the following databases up to October 2016: the Cochrane Skin Group Specialised Register, CENTRAL, MEDLINE, Embase, and LILACS. We also searched five trials registers and checked the reference lists of included and excluded studies for further references to relevant randomised controlled trials (RCTs). We sought to identify unpublished and ongoing trials by correspondence with authors and by contacting relevant pharmaceutical companies. SELECTION CRITERIA: RCTs comparing oral antifungal treatment to placebo or another oral antifungal treatment in participants with toenail onychomycosis, confirmed by one or more positive cultures, direct microscopy of fungal elements, or histological examination of the nail. DATA COLLECTION AND ANALYSIS: We used standard methodological procedures expected by Cochrane. MAIN RESULTS: We included 48 studies involving 10,200 participants. Half the studies took place in more than one centre and were conducted in outpatient dermatology settings. The participants mainly had subungual fungal infection of the toenails. Study duration ranged from 4 months to 2 years.We assessed one study as being at low risk of bias in all domains and 18 studies as being at high risk of bias in at least one domain. The most common high-risk domain was 'blinding of personnel and participants'.We found high-quality evidence that terbinafine is more effective than placebo for achieving clinical cure (risk ratio (RR) 6.00, 95% confidence interval (CI) 3.96 to 9.08, 8 studies, 1006 participants) and mycological cure (RR 4.53, 95% CI 2.47 to 8.33, 8 studies, 1006 participants). Adverse events amongst terbinafine-treated participants included gastrointestinal symptoms, infections, and headache, but there was probably no significant difference in their risk between the groups (RR 1.13, 95% CI 0.87 to 1.47, 4 studies, 399 participants, moderate-quality evidence).There was high-quality evidence that azoles were more effective than placebo for achieving clinical cure (RR 22.18, 95% CI 12.63 to 38.95, 9 studies, 3440 participants) and mycological cure (RR 5.86, 95% CI 3.23 to 10.62, 9 studies, 3440 participants). There were slightly more adverse events in the azole group (the most common being headache, flu-like symptoms, and nausea), but the difference was probably not significant (RR 1.04, 95% CI 0.97 to 1.12; 9 studies, 3441 participants, moderate-quality evidence).Terbinafine and azoles may lower the recurrence rate when compared, individually, to placebo (RR 0.05, 95% CI 0.01 to 0.38, 1 study, 35 participants; RR 0.55, 95% CI 0.29 to 1.07, 1 study, 26 participants, respectively; both low-quality evidence).There is moderate-quality evidence that terbinafine was probably more effective than azoles for achieving clinical cure (RR 0.82, 95% CI 0.72 to 0.95, 15 studies, 2168 participants) and mycological cure (RR 0.77, 95% CI 0.68 to 0.88, 17 studies, 2544 participants). There was probably no difference in the risk of adverse events (RR 1.00, 95% CI 0.86 to 1.17; 9 studies, 1762 participants, moderate-quality evidence) between the two groups, and there may be no difference in recurrence rate (RR 1.11, 95% CI 0.68 to 1.79, 5 studies, 282 participants, low-quality evidence). Common adverse events in both groups included headache, viral infection, and nausea.Moderate-quality evidence shows that azoles and griseofulvin probably had similar efficacy for achieving clinical cure (RR 0.94, 95% CI 0.45 to 1.96, 5 studies, 222 participants) and mycological cure (RR 0.87, 95% CI 0.50 to 1.51, 5 studies, 222 participants). However, the risk of adverse events was probably higher in the griseofulvin group (RR 2.41, 95% CI 1.56 to 3.73, 2 studies, 143 participants, moderate-quality evidence), with the most common being gastrointestinal disturbance and allergic reaction (in griseofulvin-treated participants) along with nausea and vomiting (in azole-treated participants). Very low-quality evidence means we are uncertain about this comparison's impact on recurrence rate (RR 4.00, 0.26 to 61.76, 1 study, 7 participants).There is low-quality evidence that terbinafine may be more effective than griseofulvin in terms of clinical cure (RR 0.32, 95% CI 0.14 to 0.72, 4 studies, 270 participants) and mycological cure (RR 0.64, 95% CI 0.46 to 0.90, 5 studies, 465 participants), and griseofulvin was associated with a higher risk of adverse events, although this was based on low-quality evidence (RR 2.09, 95% CI 1.15 to 3.82, 2 studies, 100 participants). Common adverse events included headache and stomach problems (in griseofulvin-treated participants) as well as taste loss and nausea (in terbinafine-treated participants). No studies addressed recurrence rate for this comparison.No study addressed quality of life. AUTHORS' CONCLUSIONS: We found high-quality evidence that compared to placebo, terbinafine and azoles are effective treatments for the mycological and clinical cure of onychomycosis, with moderate-quality evidence of excess harm. However, terbinafine probably leads to better cure rates than azoles with the same risk of adverse events (moderate-quality evidence).Azole and griseofulvin were shown to probably have a similar effect on cure, but more adverse events appeared to occur with the latter (moderate-quality evidence). Terbinafine may improve cure and be associated with fewer adverse effects when compared to griseofulvin (low-quality evidence).Only four comparisons assessed recurrence rate: low-quality evidence found that terbinafine or azoles may lower the recurrence rate when compared to placebo, but there may be no difference between them.Only a limited number of studies reported adverse events, and the severity of the events was not taken into account.Overall, the quality of the evidence varied widely from high to very low depending on the outcome and comparison. The main reasons to downgrade evidence were limitations in study design, such as unclear allocation concealment and randomisation as well as lack of blinding.
[Mh] Termos MeSH primário: Antifúngicos/uso terapêutico
Azóis/uso terapêutico
Dermatoses do Pé/tratamento farmacológico
Griseofulvina/uso terapêutico
Naftalenos/uso terapêutico
Onicomicose/tratamento farmacológico
[Mh] Termos MeSH secundário: Administração Oral
Adulto
Idoso
Antifúngicos/administração & dosagem
Antifúngicos/efeitos adversos
Azóis/administração & dosagem
Azóis/efeitos adversos
Feminino
Griseofulvina/administração & dosagem
Griseofulvina/efeitos adversos
Seres Humanos
Masculino
Meia-Idade
Naftalenos/administração & dosagem
Naftalenos/efeitos adversos
Ensaios Clínicos Controlados Aleatórios como Assunto
Recidiva
Prevenção Secundária
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (Antifungal Agents); 0 (Azoles); 0 (Naphthalenes); 32HRV3E3D5 (Griseofulvin); G7RIW8S0XP (terbinafine)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170908
[Lr] Data última revisão:
170908
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170715
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD010031.pub2


  5 / 4709 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28483734
[Au] Autor:Ayatollahi J; Bafghi AF; Shahcheraghi SH
[Ad] Endereço:Department of Infectious Diseases, Infectious Diseases Research Center, Shadid Sadoughi University of Medical Sciences, Yazd, Iran. shahcheraghih@gmail.com.
[Ti] Título:Leishmaniasis of the Feet Sole: A Case Report.
[So] Source:Turkiye Parazitol Derg;41(1):48-49, 2017 Mar.
[Is] ISSN:2146-3077
[Cp] País de publicação:Turkey
[La] Idioma:eng
[Ab] Resumo:Here we report the case of a patient with cutaneous leishmaniasis, who was referred to our clinic in Yazd, Iran. On examining the patient, who was a housekeeper, we found a small plaque in the palmoplantar region due to cutaneous leishmaniasis. She had not any history from an identical case in this patient. After treatment, the lesions improved.
[Mh] Termos MeSH primário: Dermatoses do Pé/diagnóstico
Dermatoses do Pé/parasitologia
Antepé Humano
Leishmaniose Cutânea/diagnóstico
[Mh] Termos MeSH secundário: Adulto
Antiprotozoários/administração & dosagem
Antiprotozoários/uso terapêutico
Feminino
Dermatoses do Pé/tratamento farmacológico
Dermatoses do Pé/patologia
Antepé Humano/parasitologia
Antepé Humano/patologia
Seres Humanos
Injeções Intramusculares
Irã (Geográfico)
Leishmania/isolamento & purificação
Leishmaniose Cutânea/tratamento farmacológico
Leishmaniose Cutânea/patologia
Meglumina/administração & dosagem
Meglumina/uso terapêutico
Compostos Organometálicos/administração & dosagem
Compostos Organometálicos/uso terapêutico
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antiprotozoal Agents); 0 (Organometallic Compounds); 6HG8UB2MUY (Meglumine); 75G4TW236W (meglumine antimoniate)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171108
[Lr] Data última revisão:
171108
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170510
[St] Status:MEDLINE
[do] DOI:10.5152/tpd.2017.4713


  6 / 4709 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28403112
[Au] Autor:Palomo-López P; Becerro-de-Bengoa-Vallejo R; Losa-Iglesias ME; Rodríguez-Sanz D; Calvo-Lobo C; López-López D
[Ad] Endereço:aUniversity Center of Plasencia, Universidad de Extremadura bSchool of Nursing, Physiotherapy and Podiatry, Universidad Complutense de Madrid cFaculty of Health Sciences, Universidad Rey Juan Carlos dPhysical Therapy & Health Sciences Research Group Department, Faculty of Health, Exercise and Sport, European University of Madrid, Villaviciosa de Odón, Madrid eNursing and Physical Therapy Department, Institute of Biomedicine (IBIOMED), Faculty of Health Sciences, University of León, Ponferrada, León fResearch, Health and Podiatry Unit, Department of Health Sciences, Faculty of Nursing and Podiatry, Universidade da Coruña, Spain.
[Ti] Título:Footwear used by older people and a history of hyperkeratotic lesions on the foot: A prospective observational study.
[So] Source:Medicine (Baltimore);96(15):e6623, 2017 Apr.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Inadequate footwear, painful and hyperkeratotic lesions (HL) are an extremely common problems amongst older people. Such problems increase the risk of falls, hamper mobility, reduction of quality of life, dignity, and ability to remain independent. The etiology of painful and feet conditions is poorly understood.To discover footwear preferences of older people, pain tolerance may favor presence of HL for the use of inadequate footwear in old age.A sample of 100 participants with a mean age of 74.90 ±â€Š7.01 years attended an outpatient clinic where self-reported demographic data, frequency with which they checked their feet were recorded and measurements were taken of foot sensitivity. Additionally, all participants' shoes were allocated into optimal, adequate, and dangerous categories based on design, structural and safety features, and materials.Only 12% of the sample population checked their feet every day, 37% revealed symptoms of neuropathy, 14% used optimal shoes, and 61% presented HL. In a bivariate analysis, no significant differences were observed.HL are associated with inadequate footwear, loss of sensitivity, and low frequency of foot health checks.
[Mh] Termos MeSH primário: Dermatoses do Pé/diagnóstico
Úlcera do Pé/diagnóstico
Sapatos/efeitos adversos
Avaliação de Sintomas/métodos
[Mh] Termos MeSH secundário: Fatores Etários
Idoso
Idoso de 80 Anos ou mais
Autoavaliação Diagnóstica
Feminino
/fisiopatologia
Dermatoses do Pé/etiologia
Úlcera do Pé/etiologia
Seres Humanos
Masculino
Doenças do Sistema Nervoso Periférico/diagnóstico
Doenças do Sistema Nervoso Periférico/etiologia
Estudos Prospectivos
Sapatos/classificação
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170430
[Lr] Data última revisão:
170430
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170414
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000006623


  7 / 4709 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Mantovani, Maria de Fátima
Marcon, Sônia Silva
Texto completo
[PMID]:28345969
[Au] Autor:Rossaneis MA; Haddad MD; Mantovani MF; Marcon SS; Pissinati PS
[Ad] Endereço:University Professor, Nursing Department, State University of Londrina, Londrina, Paraná, Brazil.
[Ti] Título:Foot ulceration in patients with diabetes: a risk analysis.
[So] Source:Br J Nurs;26(6):S6-S14, 2017 03 23.
[Is] ISSN:0966-0461
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The study reported in this article aimed to analyse factors associated with the risk of ulceration in the feet of patients with diabetes using a conceptual hierarchic model. It was a cross-sectional study carried out with 1515 people with diabetes mellitus aged 40 years and older. The risk of foot ulceration was of higher significance in male patients with diabetes (adjusted odds ratio (OR)=1.39 (95% confidence interval (CI) 1.11 to 1.73); p=0.020), who did not practise a regular physical activity (adjusted OR=1.58 (95% CI 1.15 to 2.15); p=0.013), with time since diagnosis over 10 years (adjusted OR=1.42 (95% CI 1.10 to 1.86); p=0.011), who used insulin (adjusted OR=1.40 (95% CI 1.09 to 1.84); p=0.012), with retinopathy (adjusted OR=1.84 (95% CI 1.38 to 2.45); p=0.001) and who had had a previous stroke (adjusted OR=1.47 (95% CI 1.09 to 2.04); p=0.018). Mycosis on the nails and the interdigital spaces of the feet was statistically associated with ulceration risk independent of other variables of the model (adjusted OR=2.48 (95%CI 1.70 to 3.63); p=0.001). Finding the factors associated with ulceration contributes to the provision of quality care by nurses.
[Mh] Termos MeSH primário: Diabetes Mellitus Tipo 2/tratamento farmacológico
Pé Diabético/epidemiologia
Retinopatia Diabética/epidemiologia
Exercício
Hipoglicemiantes/uso terapêutico
Insulina/uso terapêutico
Acidente Vascular Cerebral/epidemiologia
[Mh] Termos MeSH secundário: Adulto
Idoso
Brasil/epidemiologia
Estudos Transversais
Dermatomicoses/epidemiologia
Diabetes Mellitus Tipo 2/complicações
Pé Diabético/etiologia
Retinopatia Diabética/etiologia
Feminino
Dermatoses do Pé/epidemiologia
Seres Humanos
Masculino
Meia-Idade
Razão de Chances
Onicomicose/epidemiologia
Medição de Risco
Fatores de Risco
Fatores Sexuais
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Hypoglycemic Agents); 0 (Insulin)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170829
[Lr] Data última revisão:
170829
[Sb] Subgrupo de revista:N
[Da] Data de entrada para processamento:170328
[St] Status:MEDLINE
[do] DOI:10.12968/bjon.2017.26.6.S6


  8 / 4709 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28340843
[Au] Autor:Bayraktar A; Bakkaloglu H; Demir E; Turkmen A; Azamat IF; Caliskan Y; Sari SO; Buyukbabani N; Baykal C; Aydin AE
[Ad] Endereço:Department of General Surgery, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
[Ti] Título:Acquired Acrodermatitis Enteropathica Syndrome in a Kidney Transplant Receipt: A Case Report.
[So] Source:Transplant Proc;49(3):609-612, 2017 Apr.
[Is] ISSN:1873-2623
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Acrodermatitis enteropathica syndrome (AE) is a clinical entity that results in severe zinc deficiency. It can be genetic or acquired. Acquired AE has been reported in patients with chronic liver disease, malabsorption syndrome, sickle cell anemia, and chronic renal failure. We present a kidney transplant recipient with skin rash and watery diarrhea. The patient had low serum zinc levels, which quickly resolved after zinc supplementation. Skin biopsy showed cytoplasmic pallor and vacuolization and ballooning degeneration of keratinocytes within the superficial epidermis, which may have led to confluent necrosis of keratinocytes. Large amounts of keratinosome-derived lamellae were found in the intercellular spaces in the keratinized area, probably related to disturbance of keratinosome metabolism due to zinc deficiency.
[Mh] Termos MeSH primário: Acrodermatite/etiologia
Transplante de Rim/efeitos adversos
Zinco/deficiência
[Mh] Termos MeSH secundário: Acrodermatite/tratamento farmacológico
Acrodermatite/patologia
Fármacos Dermatológicos/uso terapêutico
Diarreia/etiologia
Epiderme/patologia
Dermatoses do Pé/tratamento farmacológico
Dermatoses do Pé/etiologia
Dermatoses do Pé/patologia
Dermatoses da Mão/tratamento farmacológico
Dermatoses da Mão/etiologia
Dermatoses da Mão/patologia
Seres Humanos
Queratinócitos/patologia
Falência Renal Crônica/cirurgia
Masculino
Adulto Jovem
Zinco/uso terapêutico
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Dermatologic Agents); J41CSQ7QDS (Zinc)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170531
[Lr] Data última revisão:
170531
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170326
[St] Status:MEDLINE


  9 / 4709 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28329527
[Au] Autor:Joshipura D; Goldminz A; Greb J; Gottlieb A
[Ad] Endereço:Department of Dermatology, Tufts Medical Center, Boston, Massachusetts. djoshipura@tuftsmedicalcenter.org.
[Ti] Título:Acitretin for the treatment of recalcitrant plantar warts.
[So] Source:Dermatol Online J;23(3), 2017 Mar 15.
[Is] ISSN:1087-2108
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Plantar warts caused by human papilloma virus (HPV)may be challenging to treat when conventionalmodalities fail. We report a case of severely recalcitrantplantar warts, successfully treated with oral acitretinand topical 40% urea cream.
[Mh] Termos MeSH primário: Acitretina/uso terapêutico
Dermatoses do Pé/tratamento farmacológico
Ceratolíticos/uso terapêutico
Ureia/uso terapêutico
Verrugas/tratamento farmacológico
[Mh] Termos MeSH secundário: Administração Cutânea
Administração Oral
Adulto
Doenças do Pé/tratamento farmacológico
Seres Humanos
Masculino
[Pt] Tipo de publicação:CASE REPORTS; LETTER
[Nm] Nome de substância:
0 (Keratolytic Agents); 8W8T17847W (Urea); LCH760E9T7 (Acitretin)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171017
[Lr] Data última revisão:
171017
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170323
[St] Status:MEDLINE


  10 / 4709 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:28329526
[Au] Autor:Carvalho S; Machado S; Sampaio R; Guedes M; Vasconcelos J; Semedo D; Selores M
[Ad] Endereço:Department of Dermatology, Centro Hospitalar do Porto, Oporto, Portugal. carvalhosandrine@gmail.com.
[Ti] Título:Chronic granulomatous disease as a risk factor for cutaneous lupus in childhood.
[So] Source:Dermatol Online J;23(3), 2017 Mar 15.
[Is] ISSN:1087-2108
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Chronic granulomatous disease (CGD) is a primaryimmunodeficiency disorder that affects the phagocyticcells of the innate immune system. It is characterizedby recurrent or persistent infections with granulomaformation. Lupus-like lesions have been reported incarriers of CGD and less frequently, in patients withCGD. Immunological study in these patients areusually negative. We describe the case of an 8-yearoldboy with CGD who developed chronic and acutecutaneous lupus erythematous with angular cheilitis,oral ulcers, Raynaud phenomenon, and positiveserologies for antinuclear, anticentromere, and anti-Saccharomyces cerevisiae antibodies.
[Mh] Termos MeSH primário: Dermatoses Faciais/diagnóstico
Dermatoses do Pé/diagnóstico
Doença Granulomatosa Crônica/imunologia
Lúpus Eritematoso Cutâneo/diagnóstico
[Mh] Termos MeSH secundário: Anticorpos Antinucleares/imunologia
Anticorpos Antifúngicos/imunologia
Queilite/complicações
Queilite/diagnóstico
Queilite/imunologia
Criança
Dermatoses Faciais/complicações
Dermatoses Faciais/imunologia
Dermatoses Faciais/patologia
Dermatoses do Pé/complicações
Dermatoses do Pé/imunologia
Dermatoses do Pé/patologia
Doença Granulomatosa Crônica/complicações
Seres Humanos
Lúpus Eritematoso Cutâneo/complicações
Lúpus Eritematoso Cutâneo/imunologia
Lúpus Eritematoso Cutâneo/patologia
Masculino
Úlceras Orais/complicações
Úlceras Orais/diagnóstico
Úlceras Orais/imunologia
Doença de Raynaud/complicações
Doença de Raynaud/diagnóstico
Doença de Raynaud/imunologia
Fatores de Risco
Saccharomyces cerevisiae/imunologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Antinuclear); 0 (Antibodies, Fungal); 0 (anticentromere antibody)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171017
[Lr] Data última revisão:
171017
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170323
[St] Status:MEDLINE



página 1 de 471 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde